UPMC Hillman researchers and clinicians work as a team to rapidly advance the most promising discoveries into novel clinical trials, providing patients with early access to new and innovative treatments and the most compassionate, sophisticated care.
At UPMC Hillman Cancer Center, we have a vision to bring together compassionate care and transformative research to achieve the extraordinary: life without cancer.
UPMC and University of Pittsburgh researchers will test a vaccine to prevent breast cancer in what they say is a revolutionary step in the fight against the most common cancer in women. Through the clinical trial, doctors will evaluate how well the immune system of women newly diagnosed with ductal carcinoma in situ (DCIS) respond to the vaccine, which will be administered along with the standard of care for early breast cancer.
Read More
The University of Pittsburgh was awarded a five-year grant from the National Institutes of Health (NIH) to support an Ovarian Cancer Specialized Program of Research Excellence (SPORE). The Ovarian SPORE aims to improve survival for women with ovarian cancer by improving the efficacy of therapies by preventing or overcoming therapeutic resistance.
Read More
A first of its kind clinical trial in the United States to treat glioblastoma will be launching in early 2024 at UPMC and the UPMC Hillman Cancer Center, which combines intraoperative photodynamic therapy (PDT) with the drug Pentalafen® and a new laser device Heliance®, both, developed by the French company, Hemerion Therapeutics®, sponsor of the clinical trial.
Read More